Immunic (IMUX) Share-based Compensation (2013 - 2026)

Immunic (IMUX) has 14 years of Share-based Compensation data on file, last reported at $4.5 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 118.71% year-over-year to $4.5 million; the trailing twelve-month figure through Mar 2026 stood at $2.1 billion (down 24.53% YoY), and the FY2024 full-year result was $448000.0, down 17.65% from the prior year.
• Share-based Compensation improved to $4.5 million in Q1 2026, from -$7.6 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $2.1 billion in Q3 2025 to a low of -$7.6 million in Q4 2025.
• A 5-year average of $619.2 million and a median of $4.5 million in 2026 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation soared 135.03% in 2023 and tumbled 99.77% in 2025, its largest moves.
• Tracing IMUX's Share-based Compensation over 5 years: stood at $1.9 million in 2022, then jumped by 43113.15% to $815.0 million in 2023, then sank by 100.75% to -$6.1 million in 2024, then retreated by 23.97% to -$7.6 million in 2025, then soared by 159.11% to $4.5 million in 2026.
• Business Quant data shows IMUX's Share-based Compensation at $4.5 million in Q1 2026, -$7.6 million in Q4 2025, and $2.1 billion in Q3 2025.